155 related articles for article (PubMed ID: 18660510)
1. The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab).
Buch MH; Reece RJ; Quinn MA; English A; Cunnane G; Henshaw K; Bingham SJ; Bejarano V; Isaacs J; Emery P
Rheumatology (Oxford); 2008 Oct; 47(10):1469-75. PubMed ID: 18660510
[TBL] [Abstract][Full Text] [Related]
2. Etanercept decreases synovial expression of tumour necrosis factor-α and lymphotoxin-α in rheumatoid arthritis.
Neregård P; Krishnamurthy A; Revu S; Engström M; af Klint E; Catrina AI
Scand J Rheumatol; 2014; 43(2):85-90. PubMed ID: 24313444
[TBL] [Abstract][Full Text] [Related]
3. Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients--a prospective clinical study.
Sundberg E; Grundtman C; Af Klint E; Lindberg J; Ernestam S; Ulfgren AK; Harris HE; Andersson U
Arthritis Res Ther; 2008; 10(2):R33. PubMed ID: 18346273
[TBL] [Abstract][Full Text] [Related]
4. Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor.
Ernestam S; af Klint E; Catrina AI; Sundberg E; Engström M; Klareskog L; Ulfgren AK
Arthritis Res Ther; 2006; 8(1):R18. PubMed ID: 16507118
[TBL] [Abstract][Full Text] [Related]
5. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium.
Wijbrandts CA; Dijkgraaf MG; Kraan MC; Vinkenoog M; Smeets TJ; Dinant H; Vos K; Lems WF; Wolbink GJ; Sijpkens D; Dijkmans BA; Tak PP
Ann Rheum Dis; 2008 Aug; 67(8):1139-44. PubMed ID: 18055470
[TBL] [Abstract][Full Text] [Related]
6. Application of a new immunohistology scoring system (IH score): analysis of TNF-α in synovium related to disease activity score in infliximab-treated patients with rheumatoid arthritis.
Kanbe K; Hara R; Chiba J; Inoue Y; Taguchi M; Tanaka Y
Mod Rheumatol; 2014 Nov; 24(6):910-4. PubMed ID: 24670132
[TBL] [Abstract][Full Text] [Related]
7. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study.
Klaasen R; Thurlings RM; Wijbrandts CA; van Kuijk AW; Baeten D; Gerlag DM; Tak PP
Arthritis Rheum; 2009 Nov; 60(11):3217-24. PubMed ID: 19877042
[TBL] [Abstract][Full Text] [Related]
8. Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients.
Lindberg J; af Klint E; Catrina AI; Nilsson P; Klareskog L; Ulfgren AK; Lundeberg J
Arthritis Res Ther; 2006; 8(6):R179. PubMed ID: 17134501
[TBL] [Abstract][Full Text] [Related]
9. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
van der Pouw Kraan TC; Wijbrandts CA; van Baarsen LG; Rustenburg F; Baggen JM; Verweij CL; Tak PP
Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
[TBL] [Abstract][Full Text] [Related]
11. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of rheumatoid arthritis is associated with a reduction in synovial membrane cytokines and cell adhesion molecule expression.
Smith MD; Slavotinek J; Au V; Weedon H; Parker A; Coleman M; Roberts-Thomson PJ; Ahern MJ
Rheumatology (Oxford); 2001 Sep; 40(9):965-77. PubMed ID: 11561106
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of synoviolin in peripheral blood and synoviocytes from rheumatoid arthritis patients and continued elevation in nonresponders to infliximab treatment.
Toh ML; Marotte H; Blond JL; Jhumka U; Eljaafari A; Mougin B; Miossec P
Arthritis Rheum; 2006 Jul; 54(7):2109-18. PubMed ID: 16802346
[TBL] [Abstract][Full Text] [Related]
14. The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis.
Lindberg J; Wijbrandts CA; van Baarsen LG; Nader G; Klareskog L; Catrina A; Thurlings R; Vervoordeldonk M; Lundeberg J; Tak PP
PLoS One; 2010 Jun; 5(6):e11310. PubMed ID: 20593016
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
[TBL] [Abstract][Full Text] [Related]
16. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis.
Ulfgren AK; Andersson U; Engström M; Klareskog L; Maini RN; Taylor PC
Arthritis Rheum; 2000 Nov; 43(11):2391-6. PubMed ID: 11083259
[TBL] [Abstract][Full Text] [Related]
17. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
Catrina AI; Trollmo C; af Klint E; Engstrom M; Lampa J; Hermansson Y; Klareskog L; Ulfgren AK
Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
[TBL] [Abstract][Full Text] [Related]
18. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
Buch MH; Seto Y; Bingham SJ; Bejarano V; Bryer D; White J; Emery P
Arthritis Rheum; 2005 Jan; 52(1):42-8. PubMed ID: 15641046
[TBL] [Abstract][Full Text] [Related]
19. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results.
Kavanaugh A; Rosengren S; Lee SJ; Hammaker D; Firestein GS; Kalunian K; Wei N; Boyle DL
Ann Rheum Dis; 2008 Mar; 67(3):402-8. PubMed ID: 17644541
[TBL] [Abstract][Full Text] [Related]
20. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E
Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
